Mock FDA Inspection
An FDA Consulting FirmWe specialize in Mock FDA Inspection, often referred to as an FDA Mock Inspection, and Remote Regulatory Assessments (RRA) for pharmaceutical and medical device manufacturers worldwide. Our former FDA investigators conduct realistic onsite inspections under CP 7356.002 and remote QMSR assessments under CP 7382.850 to identify compliance gaps, strengthen inspection readiness, and prepare your team for FDA scrutiny before the actual inspection.
About Our FDA Consultant
Knowledge & Experience
Don’t Settle For Less
Mock FDA Inspection by
Former FDA Investigator
A second look by a former FDA investigator can prevent serious problems later. We understand both sides because our experts have worked at the FDA and within the industry. During a mock FDA inspection, we can wear both the “white hat” and the “black hat.” This dual perspective enables CIRG’s FDA consulting to expose regulatory risks while improving operational efficiency.
Specialized Regulatory Expertise:
-
- QMSR and ISO 13485:2016: FDA’s QMSR became effective on February 2, 2026. It amends 21 CFR Part 820 and incorporates ISO 13485:2016 by reference. CIRG’s FDA consulting evaluates readiness against applicable QMSR requirements. Our mock FDA inspection aligns with the public CP 7382.850 framework to test implementation, records, management oversight, and inspection response.
- MDSAP (Medical Device Single Audit Program): CIRG conducts MDSAP readiness audits covering requirements used by Australia, Brazil, Canada, Japan, and the United States. The formal single regulatory audit must be conducted by an MDSAP-recognized Auditing Organization.
- 21 CFR Part 4 (Combination Products): CIRG helps manufacturers identify applicable CGMP requirements for drug-device combination products. Our support covers single-entity, co-packaged, and cross-labeled configurations.
- Pharmaceutical CGMP Compliance Program 7356.002: Specialized auditing for 21 CFR Part 210 (Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs), Part 211 (Finished Pharmaceuticals), 21 CFR Part 212 (PET).
An FDA mock inspection should prepare your organization for the investigator FDA is actually likely to send. FDA investigators conducting specialized inspections are trained and experienced in the products, processes, and regulatory requirements they evaluate. They may arrive with substantial FDA experience and subject-matter expertise in your area. Your mock FDA inspection should match that level of scrutiny. A former FDA investigator with direct experience in your product category can identify the weaknesses that matter most, challenge technical explanations, and test whether your systems and records will withstand specialized FDA review.
Combination Product Inspection
We are former medical device and drug investigators with experience in 21 CFR 211 (cGMP), 21 CFR 820 (QMSR), and 21 CFR Part 4
Medical Device Inspection (QMSR) CP 7382.850 & ISO 13485
Our ex-FDA investigator can assist you with preparing for your upcoming FDA inspection: QMSR under Compliance Program 7382.850 and ISO 13485.
Drug GMP Inspection (CP 7356.002)
Form FDA-483 Response
Work with a former FDA Investigator who issued numerous FDA Form 483 inspectional observations. Learn what drives regulatory escalation, and what typically triggers a Warning Letter.
Remote Regulatory Assessment (RRA)
Have a former FDA Investigator conduct your mock remote FDA inspection. Practice in real time and learn how to host FDA investigators remotely with structure, control, and confidence.
Warning Letter Response
Let a former FDA Compliance Officer who issued numerous Warning Letters assist you in preparing a precise and defensible Warning Letter response.
The Insider’s Playbook
The Inconvenient Truth a Mock FDA Inspection Reveals
The FDA does not inspect intentions. It examines whether your systems work and whether your records prove it. CIRG gives your team direct access to former FDA investigators before the inspection begins. We know how investigators follow evidence, challenge explanations, and expand their review when answers reveal deeper weaknesses. Our FDA consulting targets the issues most likely to affect the inspection. An FDA mock inspection then tests your people, records, systems, and response strategy under realistic pressure. You enter the inspection knowing your vulnerabilities, supporting evidence, and response plan.
With over 30 years of experience, we provide an “inside-out” perspective that bridges the gap between the Federal Food, Drug, and Cosmetic Act and your daily operations. We understand the high stakes: a Warning Letter can lead to millions of dollars in remediation costs, delayed approvals, lost production, and outside consulting expenses.
Our mock FDA inspection identifies critical gaps before the agency does, helping your facility remain in a state of continuous operational readiness.
The Danger of Consultant Theory vs. Investigator Reality
Why trust your mock FDA inspection to someone who has never conducted a real FDA inspection? Regulatory knowledge alone cannot replicate firsthand inspection experience. CIRG’s principal auditor served as an FDA investigator and compliance officer, then supervised FDA investigators. We have sat on the other side of the table for years. That experience drives FDA consulting grounded in how investigators follow evidence, challenge explanations, and expand inspection scope.
Remote Regulatory Assessment Readiness
FDA may conduct voluntary or mandatory Remote Regulatory Assessments. An RRA is not an FDA inspection, but its findings may influence inspection planning and regulatory decisions. CIRG tests document retrieval, version control, secure delivery, and subject-matter expert responses through a realistic mock RRA exercise.
Prepare Your Digital Response
Readiness requires more than secure connectivity. Teams must retrieve accurate records, control versions, protect confidential information, and explain quality decisions clearly.
Test People, Records, and Technology
CIRG’s FDA consulting establishes roles, response workflows, escalation paths, and document review controls. A mock FDA inspection can test screen sharing, interviews, remote facility views, and timely record production.
Address Findings Before They Escalate
FDA may use RRA findings to evaluate corrective actions, plan inspections, or support other regulatory decisions. Serious findings can lead the FDA to conduct an inspection or consider regulatory action. CIRG helps teams respond accurately, document follow-up actions, and stay ready for further FDA review.
What Is the FDA QMSR Inspection Model?
The Quality Management System Regulation (QMSR) introduces a new inspection approach for medical device manufacturers. Under the QMSR framework, investigators evaluate a manufacturer’s quality system using a structure aligned with ISO 13485 while continuing to enforce statutory requirements under the Federal Food, Drug, and Cosmetic Act.
FDA inspections conducted under the QMSR inspection model focus on how manufacturers implement quality system controls within their operations. Investigators assess whether procedures are effectively implemented, whether records support compliance, and whether management maintains appropriate oversight of manufacturing and quality activities.
The QMSR inspection model reflects the FDA’s transition toward a more harmonized approach to evaluating medical device quality systems while maintaining regulatory authority over product safety and manufacturing controls.
The Technical “Six-System” Inspection Model (CP 7356.002)
An effective mock FDA inspection should reflect applicable FDA requirements, public inspection frameworks, and realistic investigator practices. Under Compliance Program 7356.002, the inspection is conducted through a systematic “Six-System” model.
-
- Quality System: The “Sun” of your compliance. It is mandatory for every inspection and focuses on CAPA, change control, and management responsibility.
- Facilities and Equipment: Focuses on cleaning validation, HVAC, and calibration.
- Materials System: Covers supplier qualification, identity testing, and storage.
- Production System: Reviews batch records and process validation (PPQ).
- Packaging and Labeling: Focuses on line clearance and label reconciliation.
- Laboratory Control: Scrutinizes stability testing, method validation, and OOS (Out of Specification) investigations.
QMSR and Combination Products
QMSR became effective on February 2, 2026. It updated the device quality requirements referenced under 21 CFR Part 4. The applicable requirements depend on the product configuration and the manufacturer’s chosen CGMP approach.
- Drug CGMP-Based Approach: The system follows drug CGMPs plus the specific ISO 13485 and QMSR provisions listed in 21 CFR 4.4(b)(1).
- Risk Management: Applicable manufacturers must document risk-management processes for product realization. Part 4 does not universally require an ISO 14971 Risk Management File.
- Management Records: FDA may now review management review, quality audit, and supplier audit reports covered by QMSR.
CIRG’s FDA consulting identifies the requirements applicable to each product and facility. A mock FDA inspection tests readiness against the selected CGMP operating system.
What is the Drug CGMP Inspection Model?
How FDA Inspects Drug Manufacturers Under CP 7356.002
Drug inspections under Compliance Program 7356.002 use a six-system model to determine whether manufacturing operations remain in a state of control. The Quality System serves as the anchor, while investigators also examine Facilities and Equipment, Materials, Production, Packaging and Labeling, and Laboratory Control. The agency focuses on system performance, linkage between functions, management responsibility, and the reliability of quality data and records. A mock FDA inspection should therefore test more than documentation. It should challenge how systems operate together, how decisions are made, and whether problems are identified, investigated, corrected, and prevented before they become significant findings or contribute to regulatory action.
The Quality System Is the Anchor of the FDA Drug Inspection
Under CP 7356.002, the Quality System is the anchor of the drug inspection model. The agency evaluates management responsibility, quality oversight, investigations, CAPA, and whether the quality unit has sufficient authority. Weaknesses here can signal broader loss of control across manufacturing, laboratory, materials, and other operational systems throughout the inspected operation.
FDA Evaluates Whether Your Systems Are in a State of Control
The agency is not simply confirming that procedures exist. Investigators evaluate whether systems remain in a state of control and whether operations consistently produce reliable results. They examine how problems are identified, decisions are made, and corrective actions are implemented across interconnected quality and manufacturing functions within the facility in practice.
How the Six-System Drug Inspection Model Works
The six-system model covers Quality, Facilities and Equipment, Materials, Production, Packaging and Labeling, and Laboratory Control. An FDA mock inspection should examine how these systems interact rather than reviewing them as isolated functions. Problems in one system can reveal weaknesses that extend into several other systems during inspection under scrutiny.
Management Responsibility and Quality Unit Authority
Management responsibility is central to the agency’s evaluation of a drug quality system. Investigators consider whether the quality unit has appropriate authority, whether management supports effective oversight, and whether significant issues are escalated and resolved. Weak management decisions can undermine otherwise well-written procedures and documented quality responsibilities throughout operations in practice.
CAPA, Investigations, and Root Cause Effectiveness
FDA evaluates whether investigations are complete, scientifically sound, and capable of identifying meaningful root causes. Corrective and preventive actions should address identified causes and be effectively implemented. Repeated deviations, incomplete investigations, or weak follow-up can indicate that the organization has not maintained adequate control of its quality system over time.
Manufacturing Consistency, Validation, and Process Control
Manufacturing consistency depends on validated processes, appropriate controls, and reliable execution. During a mock FDA inspection, reviewers should examine whether process changes, deviations, validation activities, and production decisions remain connected. FDA looks beyond written procedures to determine whether manufacturing operations consistently perform as intended and remain under control in practice.
Laboratory Controls, Data Integrity, and Reliable Records
Laboratory controls and data reliability are critical components of drug inspections. Investigators evaluate testing, method validation, records, and whether quality data are complete, reliable, and retained. Unreliable or incomplete records can undermine confidence in product quality, release decisions, investigations, and the overall state of manufacturing control over time.
Common Systemic Failures That Lead to Form FDA 483 Observations
Systemic failures, rather than isolated documentation errors, are more likely to drive significant FDA concerns. CP 7356.002 highlights weaknesses such as inadequate quality unit authority, incomplete investigations, release of nonconforming product, insufficient validation, and unreliable records. These failures can demonstrate that an important system is not adequately controlled in practice.
Part 212 PET Drug Manufacturing Inspection Risks
Part 212 PET operations present additional high-risk concerns, including missing finished-product specifications, inadequate endotoxin or sterility testing, absent media fills, inadequate filter integrity testing, and release before required testing. An FDA mock inspection should specifically challenge these controls when PET drug manufacturing falls within the organization’s regulated operations in practice.
Continuous Inspection Readiness Matters
The inspection outcome ultimately depends on management accountability, system linkage, reliable data, and real-time decision-making. Inspection readiness is therefore not a one-time gap assessment. Organizations should continuously evaluate whether their systems remain effective, connected, and controlled so that deficiencies are identified and corrected before the agency identifies them during inspection itself.
Time is of the essence. CIRG limits FDA consulting availability because every engagement receives direct principal-level attention. Schedule your mock FDA inspection early, so your team has adequate time to prepare.
Why Every FDA-Regulated Manufacturer Needs an FDA Mock Inspection
A mock FDA inspection is one of the most valuable investments a medical device, pharmaceutical, biologic, or combination product manufacturer can make. It provides an independent assessment of your inspection readiness and quality-system performance before an investigator arrives. Unlike routine internal audits, an FDA mock inspection evaluates your quality system using the same systematic approach that investigators use during actual inspections. The assessment reviews documentation, manufacturing operations, quality records, personnel interviews, and management oversight to identify weaknesses that may result in Form 483 observations or warning letters. By identifying compliance gaps early, manufacturers have the opportunity to implement corrective actions before they become regulatory problems. A professionally conducted mock FDA inspection not only strengthens inspection readiness but also improves operational efficiency, quality system effectiveness, and confidence throughout the organization.
An FDA Mock Inspection Is More Than an Internal Audit
Many organizations believe their internal audit program is sufficient to prepare for an inspection. However, internal audits often become routine and may overlook long-standing weaknesses because auditors are familiar with existing processes and personnel. A mock FDA inspection provides an independent perspective based on real FDA inspection experience. Former FDA investigators evaluate systems using evidence, regulatory requirements, inspection techniques, and enforcement expectations developed through years of field inspections. Rather than verifying that procedures exist, they determine whether quality systems are effective and consistently implemented. This objective assessment helps management understand how investigators will likely evaluate the facility during an actual inspection. The result is a stronger quality system, improved compliance, and significantly greater confidence before an FDA inspection.
Why Choose a Former FDA Investigator?
A mock FDA inspection evaluates inspection readiness. It does not automatically satisfy your organization’s internal audit obligations. Those obligations depend on the product, governing requirements, and your documented procedures.
Under QMSR, device manufacturers must conduct internal audits at planned intervals. The regulation does not mandate one annual comprehensive audit for every manufacturer. Drug CGMP regulations also do not specifically require internal quality assurance audits.
CIRG’s professionals bring direct experience with inspection methods, interviews, records, and regulatory decision-making. Our FDA consulting helps teams anticipate likely questions and prepare clear, evidence-supported responses.
- Independent Insight: We identify overlooked gaps in procedures, records, investigations, training, and daily execution.
- Practical Risk Reduction: Addressing weaknesses early can reduce inspection disruption, remediation costs, and regulatory exposure.
- Global Support: CIRG supports manufacturers worldwide and coordinates travel efficiently when schedules permit.
- Tactical Rehearsal: An FDA mock inspection tests document retrieval, staff interviews, escalation procedures, and inspection management under realistic conditions.